Trial · NCT03274882
Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies
NCT03274882, Phase 2, Completed, Institut de Recherches Internationales Servier
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies. Trials, record NCT03274882. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03274882
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies
- NCT number
- NCT03274882
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 26 participants, actual
- Lead sponsor
- Institut de Recherches Internationales Servier
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- S95005
- First posted
- 2017-09-07
- Last updated
- 2024-07-25
- Other registries' IDs
- isrctn:ISRCTN14228310
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival (PFS) rate | at 2 months | percentage of patients alive without investigator-assessed radiological disease progression according to RECIST 1.1 after 2 months |
| Secondary | Progression-Free Survival (PFS). | Through study completion, an average of 12 weeks | based on Investigator review of the images according to RECIST 1.1 |
| Secondary | Overall Response Rate (ORR). | Through study completion, an average of 12 weeks | based on Investigator review of the images according to RECIST 1.1 |
| Secondary | Disease Control Rate (DCR) | Through study completion, an average of 12 weeks | based on Investigator review of the images according to RECIST 1.1 |
| Secondary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Through study completion, an average of 12 weeks | |
| Secondary | Abnormalities in laboratory tests (haematology, blood biochemistry and urinalysis) [safety and tolerability] | Through study completion, an average of 12 weeks | |
| Secondary | Abnormalities in physical examination and performance status (ECOG) [safety and tolerability] | Through study completion, an average of 12 weeks | |
| Secondary | Abnormalities in blood pressure [safety and tolerability] | Through study completion, an average of 12 weeks | |
| Secondary | Abnormalities in heart rate [safety and tolerability] | Through study completion, an average of 12 weeks | |
| Secondary | Abnormalities in body temperature [safety and tolerability] | Through study completion, an average of 12 weeks |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03274882
GET https://conductscience.org/api/trials/v1/NCT03274882/registered